Company introduction

Company introduction


Beijing Sinogenetic Biotechnology Co., Ltd. was established in 2021. Relying on the parent company's animal cloning and gene editing technology platform, the company has developed and constructed multi-species (dog/pig/cat/rabbit/mouse/rat) gene editing animal models, set up drug analysis and evaluation platforms such as pharmacological efficacy, pharmaco toxicology and safety evaluation, and established multi-omics analysis, imaging electrophysiology and behavioral analysis platforms. For , It provides full-process services of preclinical CRO based on multi-breed gene editing model animal development and application for drug development and device evaluation, especially for innovative drug development such as gene therapy and cell therapy.


  • oint laboratory of domestic dogs

  • Postdoctoral Program

  • Large animal model innovation platform

  • National high-tech enterprises

Model animal

Model animal

Beijing Sinogenetic Biotechnology Co., Ltd. was established in 2021.?Relying on the parent company's animal cloning and gene editing technology platform, the company has developed and constructed multi-species (dog/pig/cat/rabbit/mouse/rat) gene editing animal models, set up drug analysis and evaluation platforms such as pharmacological efficacy, pharmaco toxicology and safety evaluation platforms,?and established multi-omics analysis, imaging electrophysiology and behavioral analysis platforms.?It provides full-process preclinical CRO services on multi-breed gene editing model animal development and application for drug development and device evaluation, especially for innovative drug development such as gene therapy and cell therapy.?

Preclinical evaluation

preclinical CRO services

Topic article

Subjects & Articles

XML 地图 | Sitemap 地图

欧洲杯下注官网